Reasons for and time to seeking healthcare in cardiac clinics by women with a history of successfully treated breast cancer
E.A. Kushnareva- E.Yu. Zorina
- O.M. Moiseeva
Published 2023-06-30
Keywords
- Anthracyclines,
- Breast Neoplasms,
- Cardiotoxicity,
- Female,
- Heart Valve Diseases
- Radiotherapy ...More
How to Cite
Copyright (c) 2023 Kushnareva E.A., Astafurova O.E., Zorina E.Yu., Moiseeva O.M.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Background: Various methods of breast cancer treatment are potentially cardiotoxic: anthracycline chemotherapy, HER2-targeted therapy, and radiation therapy to the left side of the chest. In clinical practice, cardiologists deal with a wide range of complications caused by the mentioned methods.
Objective: To analyze the reasons for and timing of seeking healthcare in cardiac clinics by women with a history of successfully treated breast cancer.
Methods: Our single-center retrospective observational study included 125 women (mean age at the time of seeking healthcare was 68.1 ± 8.6 years).
Results: Patients with a history of radiation therapy had higher peak velocity (P = .015) and peak gradient (P = .017) across the aortic valve. As part of their examination and treatment 71 patients underwent coronary angiography. Of them, 21 patients (29.6%) had coronary artery stenting, and 23 patients (32.4%) underwent coronary artery bypass grafting. Forty-two patients (33.6%) underwent heart valve replacement: aortic valve replacement in 92.9% of the cases (n = 39) and mitral valve replacement in 7.1% of the cases (n = 3). We found a strong negative correlation between the age at the time of radiation therapy and the time to onset of valvular heart disease (r = −0.748; P = .000004) and an average negative correlation between the age and the time to surgical treatment (r = −0.695; P = .00003).
Conclusion: We studied the main reasons for seeking healthcare in cardiac clinics by women with a history of breast cancer, analyzed cardiac operations in terms of antitumor therapy types, and found a strong correlation between the age at the time of antitumor therapy and the time to onset of valvular heart disease, as well as the time to cardiac surgery.
Received 20 November 2022. Revised 21 May 2023. Accepted 31 May 2023.
Funding: The study was supported by Ministry of Science and Higher Education of Russian Federation (No. 075-15-2022-301).
Conflict of interest: The authors declare no conflict of interest.
Contribution of the authors: The authors contributed equally to this article.
References
- Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli M.F., Tamargo J., Torbicki A., Suter T.M.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-2801. PMID: 27567406. https://doi.org/10.1093/eurheartj/ehw211
- Gabani M., Castañeda D., Nguyen Q.M., Choi S.-K., Chen C., Mapara A., Kassan A., Gonzalez A.A., Khataei T., Ait-Aissa K., Kassan M. Association of cardiotoxicity with doxorubicin and trastuzumab: a double-edged sword in chemotherapy. Cureus. 2021;13(9):e18194. PMID: 34589374; PMCID: PMC8459919. https://doi.org/10.7759/cureus.18194
- Mitchell J.D., Cehic D.A., Morgia M., Bergom C., Toohey J., Guerrero P.A., Ferencik M., Kikuchi R., Carver J.R., Zaha V.G., Alvarez-Cardona J.A., Szmit S., Daniele A.J., Lopez-Mattei J., Zhang L., Herrmann J., Nohria A., Lenihan D.J., Dent S.F. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society. JACC CardioOncol. 2021;3(3):360-380. PMID: 34604797; PMCID: PMC8463721. https://doi.org/10.1016/j.jaccao.2021.06.003
- Darby S.C., Ewertz M., McGale P., Bennet A.M., Blom-Goldman U., Brønnum D., Correa C., Cutter D., Gagliardi G., Gigante B., Jensen M.-B., Nisbet A., Peto R., Rahimi K., Taylor C., Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. PMID: 23484825. https://doi.org/10.1056/NEJMoa1209825
- Szigeti A., Szigeti E., Grajda A. Radiation therapy for the elderly — change of concepts in breast cancer? Transl Cancer Res. 2020;9(Suppl 1):S131-S138. PMID: 35117956; PMCID: PMC8799099. https://doi.org/10.21037/tcr.2019.06.48
- Nabiałek-Trojanowska I., Lewicka E., Wrona A., Kaleta A.M., Lewicka-Potocka Z., Raczak G., Dziadziuszko R. Cardiovascular complications after radiotherapy. Cardiol J. 2020;27(6):836-847. PMID: 30338841; PMCID: PMC8079093. https://doi.org/10.5603/CJ.a2018.0120
- van Rijswijk J.W., Farag E.S., Bouten C.V.C., de Boer O.J., van der Wal A., de Mol B.A.J.M., Kluin J. Fibrotic aortic valve disease after radiotherapy: an immunohistochemical study in breast cancer and lymphoma patients. Cardiovasc Pathol. 2020;45:107176. PMID: 31837504. https://doi.org/10.1016/j.carpath.2019.107176
- Frattini S., Troise G., Fucci C., Pressman G.S., Faggiano P. Aortic valve stenosis and cancer: a common and complex association. Expert Rev Cardiovasc Ther. 2021;19(4):289-299. PMID: 33688784. https://doi.org/10.1080/14779072.2021.1902306
- Murbraech K., Wethal T., Smeland K.B., Holte H., Loge J.H., Holte E., Rösner A., Dalen H., Kiserud C.E., Aakhus S. Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: a national cross-sectional study. JACC Cardiovasc Imaging. 2016;9(3):230-239. PMID: 26897666. https://doi.org/10.1016/j.jcmg.2015.06.028
- Boekel N.B., Jacobse J.N., Schaapveld M., Hooning M.J., Gietema J.A., Duane F.K., Taylor C.W., Darby S.C., Hauptmann M., Seynaeve C.M., Baaijens M.H.A., Sonke G.S., Rutgers E.J.T., Russell N.S., Aleman B.M.P., van Leeuwen F.E. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. Br J Cancer. 2018;119(4):408-418. PMID: 30065254; PMCID: PMC6133926. https://doi.org/10.1038/s41416-018-0159-x
- Трякин А.А., Бесова Н.С., Волков Н.М., Гладков О.А., Карасева В.В., Сакаева Д.Д., Фадеева Н.В., Федянин М.Ю. Практические рекомендации по общим принципам проведения противоопухолевой лекарственной терапии. Злокачественные опухоли. 2022;12(3s2-1):27-40. https://doi.org/10.18027/2224-5057-2022-12-3s2-27-40 Tryakin A.A., Besova N.S., Volkov N.M., Gladkov O.A., Karaseva V.V., Sakaeva D.D., Fadeeva N.V., Fedyanin M.Yu. Practical recommendations on the general principles of anticancer drug therapy. Zlokačestvennye opuholi = Malignant Tumours. 2022;12(3s2-1):27-40. https://doi.org/10.18027/2224-5057-2022-12-3s2-27-40
- Gujral D.M., Lloyd G., Bhattacharyya S. Radiation-induced valvular heart disease. Heart. 2016;102(4):269-276. PMID: 26661320. https://doi.org/10.1136/heartjnl-2015-308765
- Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. PMID: 36017568. https://doi.org/10.1093/eurheartj/ehac244